Notching tumor: Signaling through Notch receptors improves antitumor T cell immunity. (3rd May 2016)

• Record Type: Journal Article
• Authors: Uzhachenko, Roman; Shanker, Anil
• Is Part Of: Oncoimmunology. Volume 5:Number 5(2016)
• Publication Date: 2016-05-03
• Subjects: Adoptive T cell therapy -- antitumor immunity -- bortezomib -- cancer immunotherapy -- Delta-like ligands -- immunosuppression -- Notch signaling; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2015.1122864
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Notch signaling is crucial for lymphocyte effector and memory differentiation. While tumor suppress Notch signaling in antitumor lymphocytes, recent studies show that the pharmacological Delta-like ligand-1 multivalent cluster or proteasome inhibitor bortezomib can restore Notch–NF-κB signaling in T cells of tumor-bearing hosts with a potential to overcome cancer cell resistance to therapy.